Adding docetaxel to androgen-deprivation therapy improved overall survival by nearly 17 months in men with high-volume metastatic hormone-sensitive prostate cancer.
Original Article: Update Sustains OS Benefit of Chemohormonal Therapy in High-Volume Prostate Cancer
NEXT ARTICLE